ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
22 announcements with these filters
Kabra Drugs Ltd reported revenue from operations of ₹32 Cr (+61.6% YoY) and net profit of ₹1.9 Cr (+5.6% YoY) for Q2 FY27.
Kabra Drugs (now Aanjaay Industries) intimated a board meeting on 6 November 2026 to consider unaudited results for the quarter ended 30 September 2026. The filing is advance notice only.
The company has filed its quarterly shareholding pattern for the period ending September 30, 2026. The document discloses the distribution of shareholding among various categories of investors.
Aanjaay Industries Limited conducted its 37th Annual General Meeting on September 30, 2026. Shareholders transacted business including the adoption of financial statements and director appointments.
Aanjaay Industries Ltd has submitted its Annual Report for FY 2025-2026 and issued notice for its 37th AGM scheduled for 30th September 2026.
Aanjaay Industries Limited announced book closure dates from September 24th to September 30th, 2026, for its Annual General Meeting scheduled for September 30th, 2026.
Aanjaay Industries Limited announced the notice for its 37th Annual General Meeting and approved board agenda items, including the appointment of directors and auditors.
Aanjaay Industries Limited has shifted its registered office from Indore, Madhya Pradesh, to Chennai, Tamil Nadu, effective August 28, 2026.
Aanjaay Industries Limited has scheduled a board meeting for September 2, 2026. The agenda includes approving the Director's Report and fixing details for the upcoming AGM.
Aanjaay Industries Limited has filed its updated Board and Committee composition list in compliance with SEBI (LODR) regulations.
Director Ms. Anand Anitha has resigned from the Board of Aanjaay Industries Limited, effective August 12, 2026, citing personal reasons.
Kabra Drugs Ltd reported revenue from operations of ₹46.2 Cr (+541.7% YoY) and net profit of ₹2.1 Cr for Q1 FY27.
Aanjaay Industries Limited will hold a Board Meeting on 12th August 2026. The meeting will consider the unaudited financial results and a Director's resignation.
Kabra Drugs Ltd has filed its quarterly shareholding pattern for the quarter ended June 30, 2026, in compliance with SEBI regulatory requirements.
Kabra Drugs Ltd has changed its name to Aanjaay Industries Limited effective July 6, 2026. The fresh Certificate of Incorporation has been filed with BSE.
Kabra Drugs plans a ₹200 Crore pharmaceutical plant in Chhattisgarh. This expansion aims to boost manufacturing capacity and long-term growth.
Kabra Drugs Ltd shareholders approved a name change and alteration of the MOA object clause via postal ballot. Both resolutions passed with 99.85% votes in favor.
Kabra Drugs Limited reported a turnaround FY26 with ₹93.23 Crore Total Income and positive PAT. The company is expanding into pharmaceutical manufacturing and AI-led defense technologies.
Kabra Drugs Ltd reported revenue from operations of ₹35.4 Cr and net profit of ₹1.1 Cr (+175.0% YoY) for Q4 FY26.
Kabra Drugs reported a total income of ₹93.23 Crore and a net profit of ₹4.96 Crore for FY2026. The Board approved these audited results today.
Kabra Drugs scheduled a board meeting for May 29, 2026, to approve quarterly financial results. The trading window remains closed for designated persons until result announcement.
Kabra Drugs received a waiver for ₹0.76 Crore in BSE penalties regarding board composition non-compliance. The exchange accepted the company's waiver application.